Skip to Content

Mesoblast Ltd ADR MESO Stock Quote

| Rating as of

NASDAQ:MESO

Morningstar‘s Stock Analysis MESO

Valuation
Currency in USD
Is it the right time to buy or sell?
Is it the right time to buy or sell?

1-Star Price

INVESTOR

5-Star Price

INVESTOR

Economic Moat

INVESTOR

About Quantitative Ratings

Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.

Key Statistics MESO

Company Profile MESO

Business Description

Mesoblast Ltd is a clinical-stage biotechnology company. It develops and commercializes innovative allogeneic cellular medicines to treat complex diseases resistant to the conventional standard of care. Its portfolio of Phase 3 product candidates comprises remestemcel-L for the treatment of steroid-refractory acute graft versus host disease (SR-aGVHD), and for moderate to severe acute respiratory distress syndrome (ARDS) and others.

Contact
Level 38, 55 Collins Street
Melbourne, VIC, 3000, Australia
T +61 396396036
Industry Biotechnology
Most Recent Earnings Sep 30, 2022
Fiscal Year End Jun 30, 2023
Employees 77